VV913 not checked

Vigonvita Life Sciences

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“VV913 10mg Capsules, taken orally on demand, 0.5-4 hours prior to sexual intercourse”In the company’s words, NCT07722780 on ClinicalTrials.gov
Tested for
Premature Ejaculation
Main trialPhase 2
“This trial adopted a multicenter, randomized, double-blind, placebo-controlled design and consisted of two parts: Part Ⅰ and Part Ⅱ.”In the company’s words, NCT07722780 on ClinicalTrials.gov

Other drugs for Premature Ejaculation

All 2 drugs for Premature Ejaculation

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 31 Dec 2027 Evaluate the Efficacy and Safety of VV913 Capsules in the Treatment of PE
Phase 1Recruiting Sep 2026 Study of the Safety, Tolerability, Pharmacokinetics of VV913 Capsules in Chinese Healthy Participants
Phase 1Recruiting 31 Dec 2026 Study of Food Effects of VV913 Capsules in Chinese Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow VV913

Following is part of Solo: you see every change to VV913 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in